Synergy CHC (SNYR) Competitors $2.94 +0.04 (+1.38%) As of 08/22/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock SNYR vs. IPA, ALTS, ZURA, TARA, AVTX, ZNTL, CRBP, SAVA, SPRO, and HLVXShould you be buying Synergy CHC stock or one of its competitors? The main competitors of Synergy CHC include ImmunoPrecise Antibodies (IPA), ALT5 Sigma (ALTS), Zura Bio (ZURA), Protara Therapeutics (TARA), Avalo Therapeutics (AVTX), Zentalis Pharmaceuticals (ZNTL), Corbus Pharmaceuticals (CRBP), Cassava Sciences (SAVA), Spero Therapeutics (SPRO), and HilleVax (HLVX). These companies are all part of the "pharmaceutical products" industry. Synergy CHC vs. Its Competitors ImmunoPrecise Antibodies ALT5 Sigma Zura Bio Protara Therapeutics Avalo Therapeutics Zentalis Pharmaceuticals Corbus Pharmaceuticals Cassava Sciences Spero Therapeutics HilleVax ImmunoPrecise Antibodies (NASDAQ:IPA) and Synergy CHC (NASDAQ:SNYR) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations. Do analysts recommend IPA or SNYR? ImmunoPrecise Antibodies currently has a consensus price target of $4.00, suggesting a potential upside of 25.00%. Synergy CHC has a consensus price target of $10.00, suggesting a potential upside of 240.14%. Given Synergy CHC's stronger consensus rating and higher possible upside, analysts plainly believe Synergy CHC is more favorable than ImmunoPrecise Antibodies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImmunoPrecise Antibodies 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Synergy CHC 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Which has stronger valuation and earnings, IPA or SNYR? Synergy CHC has higher revenue and earnings than ImmunoPrecise Antibodies. ImmunoPrecise Antibodies is trading at a lower price-to-earnings ratio than Synergy CHC, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunoPrecise Antibodies$17.59M8.40-$21.69M-$0.68-4.71Synergy CHC$34.83M0.80$2.12M$0.387.74 Do institutionals and insiders hold more shares of IPA or SNYR? 6.7% of ImmunoPrecise Antibodies shares are owned by institutional investors. 6.8% of ImmunoPrecise Antibodies shares are owned by company insiders. Comparatively, 56.6% of Synergy CHC shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is IPA or SNYR more profitable? Synergy CHC has a net margin of 10.02% compared to ImmunoPrecise Antibodies' net margin of -122.10%. Synergy CHC's return on equity of -18.56% beat ImmunoPrecise Antibodies' return on equity.Company Net Margins Return on Equity Return on Assets ImmunoPrecise Antibodies-122.10% -40.62% -22.19% Synergy CHC 10.02%-18.56%20.28% Does the media refer more to IPA or SNYR? In the previous week, Synergy CHC had 8 more articles in the media than ImmunoPrecise Antibodies. MarketBeat recorded 9 mentions for Synergy CHC and 1 mentions for ImmunoPrecise Antibodies. ImmunoPrecise Antibodies' average media sentiment score of 1.95 beat Synergy CHC's score of 0.01 indicating that ImmunoPrecise Antibodies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunoPrecise Antibodies 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Synergy CHC 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummarySynergy CHC beats ImmunoPrecise Antibodies on 12 of the 16 factors compared between the two stocks. Get Synergy CHC News Delivered to You Automatically Sign up to receive the latest news and ratings for SNYR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNYR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNYR vs. The Competition Export to ExcelMetricSynergy CHCCONS PD IndustryStaples SectorNASDAQ ExchangeMarket Cap$27.76M$33.74B$16.49B$9.76BDividend YieldN/A2.53%3.03%4.06%P/E Ratio7.7440.0318.7226.05Price / Sales0.802.0747.2188.42Price / Cash11.0516.6315.0959.36Price / Book-2.247.515.826.60Net Income$2.12M$1.23B$687.69M$265.65M7 Day Performance-14.29%0.84%0.69%2.00%1 Month Performance-25.94%5.82%-1.19%0.46%1 Year PerformanceN/A25.28%4.34%18.88% Synergy CHC Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNYRSynergy CHC4.3641 of 5 stars$2.94+1.4%$10.00+240.1%+2,840.0%$27.76M$34.83M7.7440IPAImmunoPrecise Antibodies1.648 of 5 stars$2.57-4.8%$4.00+55.6%+295.1%$118.61M$17.59M-3.7880Positive NewsShort Interest ↑ALTSALT5 Sigma0.5613 of 5 stars$5.48-10.5%N/A+158.7%$118.42M$12.53M0.00170High Trading VolumeZURAZura Bio3.2015 of 5 stars$1.73-0.6%$14.00+709.2%-43.7%$118.29MN/A-2.473News CoverageAnalyst ForecastAnalyst RevisionTARAProtara Therapeutics1.7771 of 5 stars$3.05-5.3%$19.60+542.6%+43.3%$117.67MN/A-1.8830News CoverageAnalyst RevisionAVTXAvalo Therapeutics3.3774 of 5 stars$8.90-1.8%$30.00+237.1%+9.8%$117.04M$440K0.0040News CoveragePositive NewsZNTLZentalis Pharmaceuticals1.7226 of 5 stars$1.59-3.0%$8.20+415.7%-37.6%$114.70M$67.43M-0.70160CRBPCorbus Pharmaceuticals4.3343 of 5 stars$9.13-1.3%$49.00+436.7%-83.6%$111.89MN/A-1.9240Positive NewsSAVACassava Sciences1.9463 of 5 stars$2.19-3.5%$2.00-8.7%-92.9%$105.80MN/A-0.8630Positive NewsSPROSpero Therapeutics3.959 of 5 stars$1.84-3.7%$5.00+171.7%+36.5%$103.55M$34.09M-1.88150News CoverageHLVXHilleVax1.1492 of 5 stars$2.06flat$2.00-2.9%+6.2%$103.29MN/A-1.4420High Trading Volume Related Companies and Tools Related Companies ImmunoPrecise Antibodies Competitors ALT5 Sigma Competitors Zura Bio Competitors Protara Therapeutics Competitors Avalo Therapeutics Competitors Zentalis Pharmaceuticals Competitors Corbus Pharmaceuticals Competitors Cassava Sciences Competitors Spero Therapeutics Competitors HilleVax Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNYR) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synergy CHC Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Synergy CHC With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access